AAS
ATNM icon

Avantax Advisory Services’s Actinium Pharmaceuticals ATNM Stock Holding History

Avantax Advisory Services’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$20.3K Hold
14,491
– – ﹤0.01% 2343
2025
Q1 		$23.3K Buy
+14,491
New +$18.4K ﹤0.01% 2214

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Avantax Advisory Services's ATNM Position: Q2 2025 in Review

Avantax Advisory Services held its Actinium Pharmaceuticals (ATNM) position steady in Q2 2025 at 14,491 shares worth $20.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2343.

Avantax Advisory Services first reported a position in ATNM in Q1 2025 and has held it in 2 quarters since. The position peaked at $23.3K in Q1 2025. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • Avantax Advisory Services held 14,491 shares of Actinium Pharmaceuticals worth $20.3K as of Q2 2025.
  • Avantax Advisory Services left its Actinium Pharmaceuticals share count unchanged in Q2 2025.
  • Actinium Pharmaceuticals made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #2343 holding.
  • Avantax Advisory Services first reported a position in Actinium Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • Avantax Advisory Services's Actinium Pharmaceuticals position peaked at $23.3K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.